Evidence mapPaperPMID 12654605Full record

ArticleCirculation2003

Mitral annular calcification predicts cardiovascular morbidity and mortality: the Framingham Heart Study.

Caroline S Fox, Ramachandran S Vasan, Helen Parise, Daniel Levy, Christopher J O'Donnell, Ralph B D'Agostino, Emelia J Benjamin, Framingham Heart Study

Registry-linked trialOpen access · bronzeAbstract read
PubMed Publisher
In one paragraph

Article in Circulation, 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06865885 (Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C Lowering), which is not on this map. Cited by 175 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
175citing papers in PubMed, 5 pooled it
6.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06865885 phase4recruitingstarted 2025, after this paper: background citation

Study of Optimal LDL-C Value Enhancement With Inclisiran in Patients With Multiple Comorbidities in Which There Are Drug-Drug Interactions Limiting LDL-C Lowering

Ran2025Enrolled100Registered outcomes4Posted comparisons0ConditionsCardiometabolic Syndrome, Drug Interactions, LDL-Cholersterol Lowering, Primary PreventionArmsInclisiran sodium 300 mg (equivalent to 284 mg inclisiran) in 1.5 mL
Open the trial in the graph
3 · Its place in the literature

Who cites it

175 citing papers in PubMed, 5 syntheses or guidelines pooled it, 460 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Article

115 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Caroline S FoxNational Heart, Lung, and Blood Institute's Framingham Heart Study, Framingham, Mass 01702-5827, USA.
Ramachandran S Vasan
Helen Parise
Daniel Levy
Christopher J O'Donnell
Ralph B D'Agostino
Emelia J Benjamin
Framingham Heart Study
Massachusetts General Hospital · USBoston University · USFramingham Heart Study · US

Funding

PRECURSORS OF STROKE INCIDENCE AND PROGNOSISR01NS017950 · BOSTON UNIVERSITY MEDICAL CAMPUS · 1985 to 2025
$8.2M
ASYMPTOMATIC LEFT VENTRICULAR DYSFUNCTIONK24HL004334 · BOSTON UNIVERSITY MEDICAL CAMPUS · 2001 to 2005
$421k
THE FRAMINGHAM HEART STUDY-N01HC25195-268025195N01HC025195 · TRUSTEES OF BOSTON UNIVERSITY · 2002 to 2005
NHLBI NIH HHS 1K24HL04334NHLBI NIH HHS N01-HC-25195NINDS NIH HHS 5R01-NS-17950
6 · The paper itself

Abstract

backgroundMitral annular calcification (MAC) has been associated with stroke in longitudinal, community-based cohorts and cardiovascular disease (CVD) outcomes in many small retrospective studies. Prospective data are limited on the relation of MAC with CVD morbidity and mortality. METHODS AND

resultsWe examined the association between MAC assessed by M-mode echocardiography and the incidence of CVD, CVD death, and all-cause death over 16 years of follow-up in the Framingham Heart Study subjects who attended a routine examination between 1979 and 1981. Cox proportional hazards models were used to estimate hazard ratios (HRs) associated with the presence of MAC for each outcome. Of 1197(445 male, 752 female) subjects who had adequate echocardiographic assessment, 14% had MAC. There were 307 incident CVD events and 621 deaths. In multivariable adjusted analyses, MAC was associated with an increased risk of incident CVD (HR, 1.5; 95% CI, 1.1, 2.0), CVD death (HR, 1.6; 95% CI, 1.1, 2.3), and all-cause death (HR, 1.3; 95% CI, 1.04, 1.6). For each 1-mm increase in MAC, the risk of incident CVD, CVD death, and all-cause death increased by approximately 10%.

conclusionsThe independent association of MAC with incident CVD and CVD death underscores that cardiac calcification is a marker of increased CVD risk.

Indexed as

AdultCalcinosisCardiomyopathiesCardiovascular DiseasesFemaleFollow-Up StudiesHumansIncidenceMaleMiddle AgedMitral ValveRisk FactorsUltrasonography

Identifiers

PMID12654605
OpenAlexW1973039380

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.